{"id":"NCT03874715","sponsor":"Sanofi","briefTitle":"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","officialTitle":"Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLogÂ® Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-11","primaryCompletion":"2020-07-08","completion":"2020-07-08","firstPosted":"2019-03-14","resultsPosted":"2023-07-21","lastUpdate":"2024-04-17"},"enrollment":210,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Insulin Aspart SAR341402","otherNames":[]},{"type":"DRUG","name":"Insulin Aspart","otherNames":["NovoLog"]},{"type":"DRUG","name":"Insulin glargine U100","otherNames":["Lantus"]}],"arms":[{"label":"Switching: NovoLog/SAR341402","type":"EXPERIMENTAL"},{"label":"Non-Switching: NovoLog","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate similarity in pharmacokinetics (PK) of SAR341402 and NovoLog after 4x4-week periods of alternating administration of SAR341402 and NovoLog compared to 16-week continuous use of NovoLog in participants with Type 1 diabetes mellitus (T1DM) also using insulin glargine.\n\nSecondary Objectives:\n\n* To compare the effects of alternating administration of SAR341402 and NovoLog with continuous use of NovoLog on immunogenicity.\n* To evaluate the safety of alternating administration of SAR341402 and NovoLog versus continuous use of NovoLog.\n* To compare other PK parameters between the two treatment arms (alternating administration of SAR341402 and NovoLog and continuous use of NovoLog).","primaryOutcome":{"measure":"Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Timepoint (AUClast) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm)","timeFrame":"0 hour (hr)(Pre-dose), 10, 20, 30, 40 & 50 minutes (min), 1hr, 1hr-10, 20, 30, 40 & 50min, 2hr, 2hr-15, 30 & 45min, 3hr, 3hr-15, 30 & 45min, 4hr, 4hr-20 & 40min, 5hr, 5hr-20 & 40min, 6hr, 6hr-30min, 7hr, 7hr-30min & 8hr post-dose on Day 112","effectByArm":[{"arm":"Switching: NovoLog/SAR341402","deltaMin":8960,"sd":18300},{"arm":"Non-switching: NovoLog","deltaMin":7190,"sd":6530}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":33,"countries":["United States"]},"refs":{"pmids":["37880868","38420944"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":99},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection"]}}